DeCure for Fanconi anemia complementation group D2
DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for Fanconi anemia complementation group D2 — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleFanconi anemia complementation group D2 maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for fanconi anemia complementation group d2 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
BRCA1 interacting DNA helicase 1 (BRIP1) — BRIP1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet agsdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 9EJ9 · 2.8 Å · ligand PHOSPHOTHIOPHOSPHORIC ACID-ADENYLATE ESTER (AGS). Experimental structure, not a prediction.
What the evidence adds up to
Fanconi anaemia complementation group D2 is one subtype of a rare autosomal recessive disorder characterised by progressive bone marrow failure, congenital abnormalities, and increased predisposition to cancer. Most patients develop bone marrow failure during childhood. The molecular mechanism underlying bone marrow failure remained elusive for a long time and is still a matter of debate. There is no cure available for Fanconi anaemia; treatment is symptomatic.
Cells from Fanconi anaemia patients are abnormally sensitive to DNA cross-linking agents such as mitomycin C. Transfection of the normal FA gene into mutant cells corrects this hypersensitivity and improves cell viability in vitro. The function of the FA gene products is still unclear. For patients lacking a compatible bone marrow transplantation donor, an experimental trial of gene therapy for group C FA was ongoing at the National Institutes of Health as of 1998.
The frequency of occurrence is greater in South African Afrikaners, sub-Saharan blacks, and Spanish gypsies than in the overall world population. This rare genetic disease occurs when two people with the recessive gene have children.
What is still missing is a clear understanding of the molecular mechanism driving bone marrow failure, a cure for any complementation group, and completed gene therapy trials with published results for group D2 specifically.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Journal of Clinical Investigation · 2012 · 287 citations · open access
Molecular pathogenesis and clinical management of Fanconi anemia
AbstractFanconi anemia (FA) is a rare genetic disorder associated with a high frequency of hematological abnormalities and congenital anomalies. Based on multilateral efforts from basic scientists and clinicians, significant advances in our knowledge of FA have been made in recent years. Here we review the clinical features, the diagnostic criteria, and the current and future therapies of FA and describe the current understanding of the molecular basis of the disease.
TGF-β: a master regulator of the bone marrow failure puzzle in Fanconi anemia
AbstractFanconi anemia (FA) is a genetic disease mainly characterized by progressive bone marrow failure (BMF), congenital abnormalities, and increased predisposition to cancer (1,2). Although most patients with FA develop BMF generally during childhood, the molecular mechanism underlying BMF has remained elusive for a long time and is still a matter of debate.
The Keio Journal of Medicine · 1998 · 0 citations · open access
Molecular Approaches to the Treatment of Fanconi Anemia: Recent Advances.
AbstractFanconi anemia (FA) is an autosomal recessive disorder that leads to aplastic anemia. Cells from FA patients are abnormally sensitive to DNA cross-linking agents such as mitomycin C. FA consists of at least five subgroups (FA-A through-E). The genes defective in the FA-C and FA-A groups have recently been cloned. Transfection of the normal FA gene into mutant cells corrects the hypersensitivity to DNA cross-linking agents and improves cell viability in vitro. The function of the FA gene products is still unclear, however. For patients lacking a compatible bone marrow transplantation donor, an experimental trial of gene therapy for group C FA is ongoing at the National Institutes of Health.
Zenodo (CERN European Organization for Nuclear Research) · 2016 · 0 citations · open access
Fanconi Anaemia: A Review
AbstractFanconi anaemia is a rare genetic disorder which leads to bone marrow failure and results in<br> decreased production of all types of blood cells. The frequency of occurrence is greater in South-<br> African Africaners,sub-saharan blacks, and spanish gypsies than in the overall world<br> population. This rare genetic disease occurs when two people with the recessive gene have<br> children. There is no cure available for falconi anaemia,the treatment for falconi anaemia is<br> symptomatic.<br> Keywords: fanconi anemia,rare genetic disease,growth factors
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
